) -- Welcome to November's Biotech Stock Mailbag Live Chat. The floor is yours.
I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.
Will FDA approve
middle-of-the-night sleeping pill Intermezzo next week? Will FDA accept
multiple myeloma drug carfilzomib for accelerated review?
(INCY - Get Report)
new myelofibrosis drug Jakafi was approved Wednesday, earlier than expected, but the stock reaction was muted. Let's discuss.
recover from its recent slump? Let's try to make sense of the changing hepatitis C therapy landscape with
gives up on embryonic stem cells. Should
Advanced Cell Technologies
do the same?
ever resolve its AMR101 patent issues?
What does the future of prostate cancer treatment look like? Can
all win, or will some of these companies lose?
Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on